A germline deletion of p14ARF but not CDKN2A in a melanoma-neural system tumour syndrome family

Human Molecular Genetics

Volumn 10, Issue 1, 2001, Pages 55-62

  Randerson Moor, Juliette A ^a   Harland, Mark ^a   Williams, Sarah ^a   Cuthbert Heavens, Darren ^a   Sheridan, Eamonn ^a   Aveyard, Joanne ^a   Sibley, Kathryn ^a   Whitaker, Linda ^a   Knowles, Margaret ^a   Bishop, Julia Newton ^a   Bishop, D Timothy ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER SUSCEPTIBILITY; CHROMOSOME 9P; CONTROLLED STUDY; EXON; FAMILY; FEMALE; GENE DELETION; GENE DISRUPTION; GENE LOSS; GENETIC CODE; GERM LINE; HUMAN; MALE; MELANOMA; NERVOUS SYSTEM TUMOR; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

EID: 0035170850     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/10.1.55     Document Type: Article

References (37)

1. A cell cycle regulator potentially involved in genesis of many tumour types
2. Complex structure and regulation of the p16 (MTS1) locus
3. INK4A transcript
4. The INK4 family of cell cycle inhibitors in cancer
5. Amplification of a gene encoding a p53-associated protein in human sarcomas
6. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations
7. Nucleolar Arf sequesters Mdm2 and activates p53
8. Interactions between the retinoblastoma protein and the oncoprotein mdm2
9. CDKN2A mutations in melanoma
10. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma
11. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds
12. Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbour mutations in the coding regions of either CDKN2B or p19(ARF)
13. Prevalence of germline mutations in p16, p19ARF, and CDK4 in familial melanoma: Analysis of a clinic based population
14. Germline mutations of the CDKN2A gene in UK melanoma families
15. CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds
16. ARF
17. A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma
18. Familial cutaneous malignant melanoma and tumours of the nervous system
19. Familial aggregation of malignant melanoma/dysplastic naevi and tumours of the nervous system: An original syndrome of tumour proneness
20. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumours
21. Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma
22. Mutation testing in melanoma families: CDKN2A, CDK4 and INK4D
23. Mutation screening of the CDKN2A promoter in melanoma families
24. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer
25. Frequency of homozygous deletion at p16/CDKN2A in primary human tumours
26. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma
27. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: Evidence for common founders and independent mutations
28. Regulation of p16(CDKN2) expression and its implications for cell immortalisation and senescence
29. Incidence of p14ARF gene deletion in high grade adult and paediatric astrocytomas
30. ARF gene in metastatic melanoma cell lines
31. Genomic alterations of the p19(ARF) encoding exons in T-cell acute lymphoblastic leukaemia
32. ARF
33. ARF act in overlapping pathways in cellular immortalisation
34. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53
35. Large genomic deletions in BRCA1 as major founder mutations among Dutch breast cancer families
36. Exon deletions and duplications in BRCA1 detected by semiquantitative polymerase chain reaction
37. TaqMan PCR-based gene dosage assay for predictive testing in individuals from a cancer family with INK4 locus haploinsufficiency